We present a review of the epidemiological evidence for relations of prostate cancer risk to circulating total and bioavailable androgens, to alterations in the metabolism of insulin-like growth factor-1 (IGF-1), and to anthropometric indices of longitudinal growth (body stature) and overweight. In addition, we review the physiological inter-relationships between insulin, growth hormone/IGF-1 axis, and sex steroid metabolism, as well as the associations of bioavailable sex steroid levels with overweight and obesity. A ®rst conclusion of this review is that, taken together, epidemiological studies have provided little support for the hypothesis that prostate cancer risk is increased in men with elevated total or biovailable testosterone (T). Although one prospective study showed an increased risk in men with low plasma sex hormone-binding globulin (SHBG) and with elevated plasma T for given levels of SHBG, this was not con®rmed by results from other cohort studies. A second conclusion is that overweight, which is generally associated with moderate reductions in both total and bioavailable plasma T, appears to be unrelated to any signi®cant increase or decrease in prostate cancer risk. However, signi®cant increases in risk have been observed for men with a taller body stature, or with elevated plasma IGF-1. IGF-1 may directly enhance prostate tumorigenesis by inhibiting apoptosis and by stimulating cell proliferation. In addition, IGF-1 downregulates the synthesis of SHBG, and enhances sex steroid synthesis. Therefore, we do not entirely rule out that due to an elevation of plasma IGF-1 levels, men at increased risk of prostate cancer also have mildly elevated plasma bioavailable T, which epidemiological studies may have failed to demonstrate because of methodological problems. Prostate Cancer and Prostatic Diseases (2000) 3, 157±172.
Introduction
Prostate cancer incidence rates are estimated to be up to 50 times higher in Western, industrialized countries, than in rural Asia or Africa. 1 ± 4 These increased incidence rates may be explained partially by improved methods for early detection of prostate cancer, 5 or by inter-ethnic differences in the prevalence of predisposing genetic factors. 3,6 ± 9 Nevertheless, there are strong indications from studies on migrants from low-risk to high-risk areas, and from time-trend studies relating changes in prostate cancer incidence rates to changes in lifestyle factors, that prostate cancer also has important environmental risk factors, which most likely include type of diet and levels of physical activity. 3 International associations, and time-trend associations, of age-standardized incidence rates with average adult body height and prevalence of obesity, 1, 10 suggest that aspects of energy metabolism and energy balance, as re¯ected by body height and body fat stores, may relate to enhanced prostate tumour development. It is a widely held view that the effects of both genetic and environmental factors on prostate cancer risk may be mediated by alterations in hormone metabolism. 3, 11 In this paper, we review major epidemiological observations concerning the relation of prostate cancer risk to the metabolism of androgens, and to insulin-like growth factor-1 (IGF-1). Then we brie¯y review epidemiological studies of the relation of prostate cancer risk to indices of obesity, and adult body height. Next we discuss the physiological inter-relationships between the metabolism of insulin, the growth-hormone/IGF-1 axis, and sex steroid metabolism, as well as the relation between bioavailable sex steroid levels and measures of overweight and obesity. In the section`Synthesis and research perspectives' we draw our major conclusions of the observations made.
Androgens The androgen hypothesis
Among the earliest scienti®c observations suggesting that endogenous hormones, notably the male sex steroids, may play a role in the development of prostate tumours, was that surgical or medical castration could dramatically improve the clinical course of advanced metastatic prostate cancer patients. 12 ± 14 Furthermore, as from the 1970s, several series of animal experiments have shown an increased incidence in spontaneous or chemically induced prostate tumours after prolonged administration of androgens (testosterone, T; dihydrotestosterone, DHT). 15 ± 20 Further indirect evidence for the relevance of androgen metabolism in prostate physiology came from the identi®cation of the 5-a-reductase type-2 enzyme (SRD5A2) and the androgen receptor (AR) in prostatic tissue. 7,21,22 5-Alpha-reductase catalyses the reduction of T to DHT, a more potent androgen that binds to the AR with a four times higher af®nity than T. 23, 24 Japanese and Chinese migrants to the USA have lower incidence rates of prostate cancer than men of African or European ancestry, and at the same time have been found to have lower 5-alpha-reductase activity. 25, 26 Finally, epidemiological studies have provided some evidence for positive associations of prostate cancer risk with speci®c polymorphisms in the SRD5A2 gene, causing increased 5-alpha-reductase enzyme activity, 6, 8, 27 and with polymorphisms in the AR gene causing increased AR transactivation. 28 ± 30 These various observations have led to the theory that prostate cancer risk may be increased in men with elevated prostatic concentrations of androgens, and especially of DHT.
Epidemiological studies of blood androgen levels and prostate cancer risk Numerous case ± control and prospective cohort studies have been conducted to examine whether prostate cancer risk is related to levels of circulating androgens and sexhormone binding globulin (SHBG). A central hypothesis underlying these studies is that prostatic concentrations of T are in¯uenced by circulating levels of bioavailable T unbound to sex-hormone binding globulin (SHBG), whereas prostatic concentrations of T, in turn, would be a major determinant of amounts of intraprostatic formation of DHT (Figure 1 ). One would thus expect prostate cancer risk to be related to circulating levels of bioavailable T.
On average, about 44% of T is tightly bound to sex hormone-binding globulin (SHBG), about 54% is more loosely bound to albumin, and less than 2% of T, generally referred to as the`free' T fraction (FT), is not protein-bound. 31 , 32 The bioavailability of T in vivo is modi®ed by capillary transit time, factors affecting the dissociation rates of T SHBG and albumin, endothelial membrane permeability, and intracellular elimination. 33, 34 In tissues 35 where the rate of steroid uptake is limited by intracellular elimination, plasma free steroid measurements reasonably re¯ect bioavailability. In other organs, including the prostate, the in vivo tissue uptake of T has been shown to exceed the amount of free sex steroid measured in vitro. In the latter case, plasma¯ow and/or dissociation rates of steroids from SHBG are rate-limiting for tissue uptake, and bioavailable T may be measured more appropriately as all non-SHBG bound, ie free, plus albumin-bound T. In epidemiological studies, where relative risks of Figure 1 Hypothetical model relating plasma bioavailable androgen levels to prostate tumour development.
Plasma androgens, IGF-1 and prostate cancer risk R Kaaks et al prostate cancer risk are estimated for relative levels of bioavailable T, the distinction between plasma bioavailable T and free T may be less important, as the two measures tend to be generally highly correlated ( b 0.90). The high correlation, between measures of bioavailable T and free T can be explained by the comparatively low variation in plasma albumin levels between healthy adult men, plus the much higher binding af®nity of T for SHBG than for albumin. 36 Some 22 case ± control studies have been conducted to examine possible relationships between circulating total and bioavailable androgens and prostate cancer risk. 37 51, 53, 56 showed no difference compared to the control group. Paradoxically, these contrasting results often reached statistical signi®cance in spite of a very small number of observations (14 out of the 22 studies on total plasma T had no more than 35 cases), which suggests that at least some results may have been due to biases.
In case ± control studies, bias may be caused by the selection of controls from a different source population (eg different socio-economic strata, with different lifestyles) than that in which cases have arisen. Likewise, bias may arise because of systematic differences between cases and controls in the conditions of blood collection (eg psychological stress, inactivity during hospitalization, anti-cancer therapy) that may affect plasma hormone concentrations. Furthermore, a crucial problem of case ± control studies is that blood samples are drawn after cancer diagnosis, which leaves doubt as to whether case ± control differences in hormone levels are indeed a possible cause or, on the contrary, a physiological consequence of the disease. Most of the biases that may occur in case ± control studies can be minimized by using a prospective cohort study design, where blood samples are obtained from healthy subjects well before the clinical manifestation of cancer, and where hormone measurements of incident cases are compared with those of a representative subset of disease-free subjects belonging to the same, well-de®ned study base.
In none of the nine prospective cohort studies, so far, 59 ± 68 was there any signi®cant relationship of prostate cancer risk with plasma total T or total SHBG (Table  1) , although one large study, within the Physicians' Health Study cohort, 63 showed a near-signi®cant decrease in prostate cancer risk with increasing SHBG levels (P 0.07). Furthermore, one study showed a positive association of risk with levels of D4-androstenedione. 67 A complication in evaluating the association of total T and SHBG with prostate cancer risk is that in men there is generally a strong positive correlation between these two hormonal parameters (see also below). Therefore, the authors of the Physicians Health Study adjusted for levels of SHBG when evaluating the associations of risk with circulating T. This multivariate analysis showed prostate cancer risk to be positively and signi®cantly associated with plasma T (relative risk (RR) between top and bottom quartiles 2.60, CI 1.34 ± 5.02) after correction for SHBG levels. Conversely, SHBG was negatively and signi®cantly related to disease risk after adjustment for plasma T (RR 0.46, CI 0.24 ± 0.89). These results thus suggested a relationship of risk with plasma bioavailable T. In another cohort, however, where plasma T was similarly adjusted for SHBG, no signi®cant associations with risk were found. 60 Furthermore, four prospective cohort studies where free or bioavailable T was measured by an ammonium sulphate precipitation technique, 60, 62, 64 or by calculation from total concentrations of T, SHBG and albumin 65 did not show any clear association of bioavailable T with prostate cancer risk.
An important issue in the interpretation of these results is the accuracy of free or bioavailable T assays. Equilibrium dialysis is generally considered the reference technique for measurement of androgen bioavailability in blood samples. 69,70 A faster method, which also has good accuracy, is based on ultra®ltration dialysis. 71 The assays based on the measurement of T after ammonium-sulphate precipitation of SHBG and albumin, or on calculation of bioavailable T from total T and SHBG levels using the known binding af®nities of T with each of these two proteins 72 have been shown to correlate reasonably well with dialysis-based methods. 36, 73, 74 No studies have been reported on the validity of T levels adjusted for levels of SHBG by regression models as an index of free T (as in Gann et al 63 and Dorgan et al 60 ). Nevertheless, within an ongoing prospective cohort study on plasma hormones and prostate cancer risk in Northern Sweden, we ourselves found a correlation of 0.98 between levels of T linearly adjusted for SHBG and free T (n 447) calculated from total T and SHBG using mass action equations (Kaaks et al unpublished results).
In several of the cohort studies prostate cancer risk was associated with levels of DHT, although not signi®cantly so (Table 1) . It is doubtful, however, whether circulating DHT levels are a reliable indicator of DHT formation speci®cally within the prostate, because a relatively large proportion of circulating DHT may be formed in skin, by the action of 5-alpha-reductase type I (an isozyme of the prostatic enzyme, 5-alpha-reductase type II). As an alternative marker of prostatic DHT formation, ®ve of the prospective studies 61 ± 64,75 examined androstane-17,3 diol-glucuronide (Adiol-G), a metabolite of DHT, as a predictor of prostate cancer risk. A recent meta-analysis of the latter three studies showed some overall evidence for a positive association of Adiol-G with prostate cancer risk, 76 which suggests that increased rates of intraprostatic conversion of T into DHT might indeed enhance prostate cancer development. Like circulating DHT, however, blood levels of Adiol-G may not re¯ect speci®cally the formation of DHT in the prostate.
Insulin-like growth factor-1 (IGF-1)
The possible relationship of cancer risk with circulating levels of IGF-1 and its binding proteins (IGFBPs) has recently received much interest from epidemiologists. The central hypothesis is that elevated IGF-1 bioactivity 77, 85, 86 and all of these are found in blood plasma. Most of IGF-1 and IGFBPs that circulate in blood are produced in the liver. Over 90% of circulating IGF-1 is complexed with IGFBP-3, and with another glycoprotein called acid-labile subunit (ALS). IGFBP-3 has a very high af®nity for IGF-1 and the large IGF-1/IGFBP-3/ALS complex cannot pass through the capillary barrier to target tissues. IGFBP-5 binds IGF-1 with an even higher af®nity than IGFBP-3, and may also form a IGF-1/IGFBP-5/ALS complex. 87, 88 Practically all of the remaining IGF-1 is bound to the IGFBPs-1, -2, -4 and -6, which have lower IGF-1 binding af®nities, and do not form complexes with ALS. 77, 85, 86 Therefore, a decrease in plasma IGFBP-3, or a relative transfer of IGF-1 from the IGFBPs-3 or -5 to smaller the IGFBPs not complexed with ALS is believed to result in increased IGF-1 availability to its tissue receptors. In addition, reductions in plasma concentrations of IGFBPs-1 and -2 (mostly in response to a rise in plasma insulin) are also thought to increase the bioavailability of circulating IGF-1. 77, 82, 84, 86 There is some evidence that IGFBP-1 may enhance active transport of IGF-1 through the endothelial barrier, in response to a rise in insulin levels. 89, 90 Alternatively, decreases in IGFBP-1 and IGFBP-2 may lead to an increase in plasma levels of free IGF-1, 91 ± 93 a small fraction of IGF-1 (`2%) that is unbound to IGFBPs or dissociates from them very readily, and that may easily diffuse into tissues. Plasma free IGF-1 correlates inversely with plasma IGFBP-1 and IGFBP-2, and positively with obesity and plasma insulin levels. 92 ± 94 At the target tissue level, IGFBPs have been mostly proposed to inhibit binding of IGF-1 to its receptors by complexing IGF-1, thus competing with the IGF-1 receptor for IGF-1 binding. Nevertheless, the results from some in vitro studies suggest that, depending on the type of IGFBP, the relative concentrations of IGF-1 and IGFBPs, and tissue type certain IGFBPs (eg IGFBPs-1, -2, -3, -5) may actually enhance IGF-1 binding to its receptors. 77, 86 For IGFBP-3 it has been shown that, while it may inhibit the anti-apoptotic action of IGF-1 by decreasing IGF-1's availability for binding to its receptor, it can itself stimulate apoptosis of breast and prostate cancer cells in vitro through a IGFBP-3-speci®c binding site on the cell membrane. 95, 96 Epidemiological studies on IGF-1 and prostate cancer risk Several recent epidemiological studies have shown an increase in prostate cancer risk in men with elevated plasma IGF-1. In the Physicians' Health Study (PHS) (the same prospective cohort study that showed an increase in prostate cancer risk at elevated plasma T for given levels of SHBG 63 ), prostate cancer risk increased with increasing plasma concentrations of IGF-1 (Table  2) . 97 A similar result was obtained in the Northern Sweden Health and Disease Study (NSHDS), another large prospective cohort. 98 In this second cohort study, the increase in risk was particularly strong in men who provided their blood sample at age 40 ± 50, and who developed a prostate tumour below age 60 (relative risks and 95% con®dence intervals of 1.00, 2.97 (0.84 ± 10.49), and 4.30 (1.19 ± 15.50), for tertiles of IGF-1). Furthermore, prostate cancer risk was positively related to total circulating IGF-1 in two case-control studies (210 and 52 cases, respectively), 99, 100 but not in a third, small prospective study that included only 45 incident cases of prostate cancer. 101 Observed associations of prostate cancer risk with IGFBP-3 have been less concordant between studies. Prostate cancer risk was not associated with total IGFBP-3 in the PHS, 97 and in one case ± control study, 100 but was positively related to IGFBP-3 levels in the NSHDS. On the other hand, in the PHS the association of prostate cancer risk with IGF-1 became stronger when IGF-1 levels were adjusted for levels of IGFBP-3 in a multivariate regression model, whereas IGFBP-3 adjusted for IGF-1 was found to be signi®cantly inversely related to risk. In the NSHDS, by contrast, adjustment for IGFBP-3 made the association of risk with IGF-1 disappear in the full cohort analysis, but had no effect on relative risk estimates when the analysis was restricted to subjects with a longer than median duration of follow-up, or when the analysis was restricted to young men recruited at age 40 ± 50. In one case ± control study, 100 IGFBP-3 levels did not differ between cases and controls, and adjustment for IGFBP-3 did not substantially alter the association of prostate cancer risk with IGF-1.
The elevated IGF-1 levels observed in men at increased risk of developing prostate cancer IGF-1 might re¯ect a relative elevation of pituitary GH secretion. Conditions of increased pituitary GH secretion, such as the pubertal growth phase, or acromegaly, are generally associated with increases not only in the total concentrations of IGF-1 and IGFBP-3, but also in the IGF-1/IGFBP-3 ratio. 102 ± 104 An increase in pituitary GH secretion could also thus underlie an increase in prostate cancer risk in men with elevated IGF-1 for given levels of IGFBP-3.
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International differences in age-standardized incidence and mortality rates of prostate cancer, and increases over time in prostate cancer incidence rates in Western populations, correlate strongly with geographical differences or time trends in the prevalence of obesity and Type-II diabetes, and with average population height. 1,10,105 ± 107 These associations suggest possible relationships of prostate cancer risk with aspects of energy metabolism and balance, which might be related to alterations in IGF-1 and androgen metabolism, during adolescence as well as later in life. This type of aggregatelevel association, however, does not provide suf®cient evidence that similar associations exist at the level of individuals, and con®rmation of such individual-level relationships requires case ± control or cohort studies.
Numerous case ± control studies 55,58,108 ± 134 and cohort studies 60,62,67,135 ± 151 have examined at the level of individuals the possible relationships of prostate cancer risk with BMI, as a general index of overweight, and with body stature. Globally, the results from these studies show no clear evidence of any substantial positive or negative association of risk with BMI (Table 3) , which we con®rmed by a formal meta-analyses of the studies listed (results not shown). A few recent studies have also addressed the possible relationship of risk with the waist-to-hip ratio of body circumferences, a more speci®c measure of abdominal fat stores, but also here no clear associations were found. 118, 128, 144 The absence of any clear association of prostate cancer risk with overweight or obesity strongly suggests that hyperinsulinaemia and related metabolic alterations (eg decreases in SHBG, IGFBP-1 and IGFBP-2) are not important factors in prostate cancer etiology. This seems to be con®rmed by the fact that prostate cancer risk has not generally been found to be increased in men with a previous history non-insulin dependent diabetes mellitus (NIDDM), 152 ± 162 even though men with NIDDM generally have elevated insulin levels. Furthermore, in the prospective NSHDS there was no signi®cant association of prostate cancer risk with direct measurements of fasting plasma insulin, IGFBP-1 or IGFBP-2. 98 Regarding adult body height, many studies do show a positive association, although very modest, with prostate cancer risk (Table 3) . A meta-analysis of the prospective studies showed a signi®cant increase in prostatic cancer risk of about 20 ± 25%, comparing upper and lower quartiles of height, and a similar increase was shown for the case ± control studies (results not shown). Adult body height is determined by longitudinal growth rates during childhood and adolescence, which is under the complex control of various hormones, notably GH, IGF-1 and androgens. A taller body stature may thus re¯ect comparatively elevated levels of these hormones during childhood and adolescence, and the positive association Role of insulin and IGF-1 in regulating androgen bioavailability
Physiological mechanisms
Numerous studies have shown an inverse relation between obesity and plasma SHBG in men. 166 ± 170 This inverse correlation is due to an obesity-related rise in fasting and non-fasting plasma insulin levels, as a consequence of insulin resistance. 171 ± 173 Insulin inhibits the production of SHBG by liver cells in vitro, 174 ± 176 and cross-sectional studies show negative correlations between plasma insulin and plasma SHBG. 168,177 ± 179 Like insulin, IGF-1 inhibits SHBG production in vitro, 174,175,180 ± 182 and total plasma IGF-1 levels also show weakly inverse correlations with plasma SHBG. 178,183 ± 185 Apart from regulating SHBG levels, insulin and IGF-1 both potentiate the luteinizing hormone (LH)-induced steroidogenesis in Leydig cells in vitro. 186 ± 188 In women, a similar stimulatory effect of insulin and IGF-1 on androgen production has been shown for the ovarian stroma, 189, 190 which in many respects resembles testicular tissue. Both insulin and IGF-1 stimulate the expression of the genes for CYP11A, 191 ± 195 an enzyme that catalyses the ®rst and rate-limiting step (cholesterol side-chain cleavage) in the formation of all steroid hormones, and for CYP17 (17-alpha-hydroxylase/17,20-lyase), 192,194 ± 196 which catalyses the ®rst two rate limiting steps in the formation speci®cally of sex steroids. 191,197 ± 199 Furthermore, insulin and IGF-1 stimulate LDL cholesterol uptake by steroidogenic tissues, and stimulate the synthesis of the steroid accrue regulatory protein (StAR), which is crucial for the intracellular transport of cholesterol to the mitochondria, where cholesterol is the starting substrate for steroid synthesis. 200 ± 203 Insulin's effects on the synthesis SHBG and sex steroids may be mediated at least partially by increases in IGF-1 bioactivity within the liver and gonads, through downregulation of IGFBP-1 and IGFBP-2. One would thus expect insulin's effect on SHBG levels to be modulated by variations in total IGF-1 levels (Figure 2) . This model is supported by the observation that, after adolescence, increasing age is associated with a gradual rise in plasma SHBG, but with a decrease in plasma total T 178,185,204 ± 209 Ð a divergence in relationships that contrasts with the generally strong coregulation (and positive correlations) between T and SHBG observed cross-sectionally. The progressive uncoupling of the coregulation between SHBG and total plasma T with increasing age may be explained by the parallel, age-related decline in pituitary GH production, and in total IGF-1 levels. 178, 210 Associations of bioavailable androgens with overweight and obesity
In women the opposite effects of insulin and IGF-1 on the synthesis of SHBG and of sex steroids, especially androgens, are re¯ected by positive associations of total or free plasma androgens with insulin. 189, 211 In men, however, total plasma T correlates inversely with body mass index (BMI weight/height 2 ) and plasma insulin levels. 168 ± 170,178,212 ± 215 The generally accepted explanation for these relationships in men is that an increase in bioavailable T causes a compensatory decrease in pituitary LH secretion (longloop feedback inhibition). An obesity-related decrease in plasma SHBG would thus lead to a downwards regulation of plasma total T, so as to keep bioavailable T relatively constant (Figure 2) . Nevertheless, in obese men (BMI b 30), as well as in men with NIDDM (who Plasma androgens, IGF-1 and prostate cancer risk R Kaaks et al generally are also hyperinsulinaemic), not only are total plasma T and SHBG, LH pulse amplitude and diurnal LH levels decreased, but also free and bioavailable T levels are reduced. 166,168,169,212 ± 214,216 ± 221 Obesity thus seems to cause a state of`hypogonadotropic hypogonadism', similar to that observed at old age. 209, 222 This state cannot be explained entirely by a negative feedback of bioavailable T on pituitary LH secretion, but must involve additional mechanisms, which are only partially understood ( Figure  2) . 221, 223, 224 One such additional mechanism may be a decrease in pituitary GH secretion and total IGF-1 levels, which is generally observed in obese men. 178, 225, 226 Another possible mechanism is the inhibition of androgen synthesis by leptin, a hormone formed predominantly in adipose tissue, which is central to the regulation of food intake, as well as to regulation of reproductive function in women and men. 227 In overweight to mildly obese men (25`BMI`30), total T is decreased, but not dramatically so, and moderate overweight or obesity usually is not associated with a state of hypogonadotropic hypogonadism. Nevertheless, several large cross-sectional studies have also shown inverse relationships of free T with BMI, the waist-to-hip ratio (WHR) or plasma insulin levels, in representative population samples of men where the vast majority had a BMI below 30. 166,167,170,212,228 ± 233 To some degree, the results from these studies may have been confounded by age, 230, 232 which generally correlates negatively with free T but positively with BMI. Nevertheless, the inverse associations of free T with BMI, WHR or insulin remained statistically signi®cant in all studies where an adjustment for age was made 166, 167, 212, 228, 229, 233 or where all subjects studied were within a very narrow age range. 170, 231 
Synthesis and research perspectives
In this review, we have evaluated available epidemiological evidence for relationships of prostate cancer risk with alterations in plasma total or bioavailable androgens, with plasmatic indices of IGF-1 bioactivity, and with conditions of chronic endogenous insulin excess (obesity, NIDDM). In addition, we have reviewed the roles of insulin and the GH/IGF-1 axis in the regulation of androgen bioavailability in men.
A ®rst conclusion from this review is that prospective cohort studies globally have not shown a clear association of prostate cancer risk with plasma levels of total T, or with plasma bioavailable T unbound to SHBG. This conclusion is somewhat unexpected, given the well-documented strong inhibition of prostate tumour progression after castration or anti-androgenic hormone therapy, and given some observations of increased prostate cancer risk in men with polymophisms in the AR and SRD5A2 genes. Possibly, prostate cancer risk is related more to intraprostatic concentrations of DHT than of T, while betweensubject variations in intraprostatic DHT formation may depend more on variations in 5a-reductase activity than on differences in bioavailable plasma T. The betweensubject variation in levels of bioavailable T is generally smaller than that in total T, due to the coregulation of T and SHBG, and thus may be only weakly associated with prostate cancer risk. Furthermore, a weak association of prostate cancer risk with plasma bioavailable T can be easily obscured by variations over time in plasma hormone levels, or by laboratory errors in the hormone measurements. Future prospective cohort studies on circulating androgens and prostate cancer risk would be strengthened by the incorporation of methodological substudies, on a representative subsample of study subjects, to evaluate the validity and reproducibility over time of measurements of bioavailable T.
A second conclusion is that obesity and NIDDM, indicators of chronic hyperinsulinaemia, are not associated with any clear increase or decrease in prostate cancer risk. One major metabolic consequence of hyperinsulinaemia is a reduction in plasma SHBG. In spite of this downregulation of SHBG, however, overweight, obesity and NIDDM have been found to be also inversely related to plasma bioavailable T. Thus, if plasma bioavailable T was indeed a major factor in the etiology of prostate cancer, one would expect obesity and NIDDM to be related to a reduction in prostate cancer risk. The apparent lack of such protective effect strengthens the idea that between-subject variations in plasma bioavailable T may not be a predominant risk factor.
A third conclusion, to be con®rmed by further prospective cohort studies, is that prostate cancer risk appears to be directly related to total plasma IGF-1 concentrations. Interestingly, prospective cohort studies have also recently shown that elevated plasma IGF-1 levels may increase the risk of breast cancer 234 ± 237 and colorectal cancer. 238 Furthermore, there appears to be a modest positive association of adult height, a possible marker of total and bioavailable IGF-1 levels during the pubertal growth spurt, with the risk of prostate cancer (Table 3) , as well as of breast cancer. 239 ± 241 Taken together, these observations suggest that elevated IGF-1 levels, perhaps especially early in life, may be a common determinant of the risk of more than one form of cancer with high incidence rates in Western, industrialized societies.
A fourth conclusion is that not only insulin, but also total IGF-1 levels, appear to have an important role in the regulation of SHBG levels. Furthermore, the progressive uncoupling of the coregulation between T and SHBG in association with the age-related decline in IGF-1 levels suggests a central importance of IGF-1 also in regulating levels of bioavailable T. Some studies have shown weak, but statistically signi®cant, positive correlations of total plasma IGF-1 with measures of bioavailable T. 184, 185 Taken together, these observations raise the intriguing question whether the inverse relationships of prostate cancer risk with SHBG observed in the Physicians' Health Study, but also in the Northern Sweden Health and Disease Study (Dr Stattin, Umea Ê University, personal communication), could not be a mere re¯ection of the positive association of risk with total plasma IGF-1 levels. These observations also leave some doubt as to whether prostate cancer risk is truly unassociated with plasma levels of bioavailable T, or whether a weak association does exist which prospective studies have failed to demonstrate because of methodological problems.
In summary, prostate cancer risk appears to have no important association with obesity and obesity-related alterations in plasma levels of total or bioavailable T. However, risk seems strongly related to total circulating Plasma androgens, IGF-1 and prostate cancer risk R Kaaks et al IGF-1 levels, and also has a weak positive association with body height, which suggests a possible relationship of risk with IGF-1 levels early in life. With regard to the latter observations, however, several major questions remain. One major question is why only increases in total IGF-1 or in IGF-1 relative to IGFBP-3 are related to prostate cancer risk, whereas increases in IGF-1 bioactivity that one would expect to result from obesity and hyperinsulinaemia (and hence reductions in IGFBPs-1 and -2) are apparently not. This relates to at least two issues. First, it is only partially understood how IGF-1 bioactivity within the prostate is quantitatively modi®ed by concentrations of various IGFBPs. As mentioned above, several of the IGFBPs either inhibit or sometimes actually potentate binding of IGF-1 to its receptor, depending on concentrations relative to IGF-1 and on the cell type studied. 77, 86 Second, it is not fully understood how circulating levels of total IGF-1 and IGFBPs may be quantitatively related to levels within the prostate. Some of the circulating IGFBPs can diffuse more easily through the endothelial barrier than others, whereas the IGFBPs may also be synthesized locally within the prostate. It is also possible however that, instead of being predominant determinants of tissue concentrations, circulating levels of IGF-1 and IGFBPs merely re¯ect the level synthesis of IGF-1 and IGFBPs within the prostate itself, as the intraprostatic synthesis may at least partially be regulated by the same factors, such as GH and insulin, that regulate the synthesis in the liver (the major source of the circulating peptides).
Another major question is which physiological mechanisms underlie the increases in circulating total IGF-1 in men at increased risk of prostate cancer, and how such mechanisms may be related to environmental risk factors, and particularly diet and levels of physical activity. Although chronic energy restriction has been shown to decrease circulating IGF-1 levels, 82, 84 obesity, a re¯ection of long-term positive energy balance, is not related to an increase in total IGF-1 compared to the normally nourished, but non-obese state. 93,94,225,226,242 ± 245 Furthermore, in well-nourished Western populations, 40 ± 60% of variation in circulating IGF-1 levels appears to be explained by genetic factors, as shown by heritability studies. 246, 247 We speculate that the large inter-individual variations in circulating IGF-1 levels re¯ect differences in pituitary GH secretion. Further research will be needed to understand how environmental (lifestyle) factors may interact with genetic susceptibility factors in determining total IGF-1 concentrations and, eventually, prostate cancer risk. Plasma androgens, IGF-1 and prostate cancer risk R Kaaks et al
